Earnings call Veracyte delivered a milestone Q2 2026 with total revenue of $150.3M, up 15% YoY, and adjusted EBITDA of $44M (29.2% margin). Management raised full-year revenue guidance to $590–$596M ...

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that the treatment is working. A recent real-world study indicates that ...

Urologists debunk common prostate cancer myths about age, symptoms, PSA testing and treatment.

Veracyte’s core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins.

A blood test taken years before cancer appears may hold a warning sign for men’s long-term health.

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator ...

Veracyte is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence. Click here to read more ...

In "Beyond Diagnosis: Metastatic Castration-Sensitive Prostate Cancer," Cleveland Clinic oncologist Christopher Wee, MD, and ...

The NHS is inviting 500,000 men with prostate cancer histories to join Prostate Progress, a research programme focused on ...

Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD ...

Veracyte swung to GAAP profitability while crushing EPS estimates by 25% in Q2, powered by 20% growth in Decipher Prostate ...

Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19%year-over-year, ...